Literature DB >> 11699896

Viruses for the treatment of malignant glioma.

M Gromeier1, E Wimmer.   

Abstract

Viruses have been considered for use as therapeutic agents against cancer, and malignant glioma in particular. Oncolytic viruses were designed to target malignant cells supporting efficient virus replication, or rendered vulnerable to viral destruction due to tumor-specific defects in their defense against virus infection. Other than conventional cancer chemotherapy, viral antineoplastic agents require complex interactions with the host organism to reach their target and to unleash their oncolytic activity. Recent progress in the design and therapeutic application of oncolytic viruses carries the promise to make these agents available for treatment of malignant glioma.

Entities:  

Mesh:

Year:  2001        PMID: 11699896

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  5 in total

1.  Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.

Authors:  Subbiah Elankumaran; Vrushali Chavan; Dan Qiao; Raghunath Shobana; Gopakumar Moorkanat; Moanaro Biswas; Siba K Samal
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

2.  Potential of equine herpesvirus 1 as a vector for immunization.

Authors:  Sascha Trapp; Jens von Einem; Helga Hofmann; Josef Köstler; Jens Wild; Ralf Wagner; Martin Beer; Nikolaus Osterrieder
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology.

Authors:  E Antonio Chiocca; William C Broaddus; George T Gillies; Therese Visted; Martine L M Lamfers
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

4.  Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.

Authors:  Helga Hofmann-Sieber; Jens Wild; Nicole Fiedler; Karsten Tischer; Jens von Einem; Nikolaus Osterrieder; Heike Hofmann; Josef Köstler; Ralf Wagner
Journal:  J Virol       Date:  2010-09-08       Impact factor: 5.103

5.  Poliovirus receptor CD155-targeted oncolysis of glioma.

Authors:  Melinda K Merrill; Guenter Bernhardt; John H Sampson; Carol J Wikstrand; Darell D Bigner; Matthias Gromeier
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.